MERIDA MERGER CORP I (MCMJ) Fundamental Analysis & Valuation

NASDAQ:MCMJ

6.53
+0.1 (+1.56%)
At close: Feb 4, 2022
6.8
+0.27 (+4.13%)
After Hours: 2/4/2022, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MCMJ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

MCMJ gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. While MCMJ seems to be doing ok healthwise, there are quite some concerns on its profitability. MCMJ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. MCMJ Profitability Analysis

1.1 Basic Checks

  • In the past year MCMJ has reported negative net income.
MCMJ Yearly Net Income VS EBIT VS OCF VS FCFMCMJ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 0 -500K -1M -1.5M

1.2 Ratios

Industry RankSector Rank
ROA -4.8%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MCMJ Yearly ROA, ROE, ROICMCMJ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 0 -0.5 -1

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MCMJ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MCMJ Yearly Profit, Operating, Gross MarginsMCMJ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MCMJ Health Analysis

2.1 Basic Checks

  • MCMJ has less shares outstanding than it did 1 year ago.
  • MCMJ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MCMJ Yearly Shares OutstandingMCMJ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 5M 10M 15M
MCMJ Yearly Total Debt VS Total AssetsMCMJ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 20M 40M 60M 80M 100M

2.2 Solvency

  • MCMJ has an Altman-Z score of 7.86. This indicates that MCMJ is financially healthy and has little risk of bankruptcy at the moment.
  • There is no outstanding debt for MCMJ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.86
ROIC/WACCN/A
WACCN/A
MCMJ Yearly LT Debt VS Equity VS FCFMCMJ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 0.49 indicates that MCMJ may have some problems paying its short term obligations.
  • MCMJ has a Quick Ratio of 0.49. This is a bad value and indicates that MCMJ is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.49
MCMJ Yearly Current Assets VS Current LiabilitesMCMJ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 100K 200K 300K 400K 500K

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MCMJ Growth Analysis

3.1 Past

  • The earnings per share for MCMJ have decreased strongly by -7423.97% in the last year.
EPS 1Y (TTM)-7423.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1082.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MCMJ is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.62% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-87.12%
EPS Next 2Y-95.74%
EPS Next 3Y-32.32%
EPS Next 5Y-0.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MCMJ Yearly Revenue VS EstimatesMCMJ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 50M 100M 150M 200M
MCMJ Yearly EPS VS EstimatesMCMJ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3 -0.4

More info and screens

Find the best growth stocksShow best growing peers

0

4. MCMJ Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MCMJ. In the last year negative earnings were reported.
  • Also next year MCMJ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MCMJ Price Earnings VS Forward Price EarningsMCMJ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MCMJ Per share dataMCMJ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as MCMJ's earnings are expected to decrease with -32.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-95.74%
EPS Next 3Y-32.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MCMJ Dividend Analysis

5.1 Amount

  • MCMJ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MCMJ Fundamentals: All Metrics, Ratios and Statistics

MERIDA MERGER CORP I

NASDAQ:MCMJ (2/4/2022, 8:00:01 PM)

After market: 6.8 +0.27 (+4.13%)

6.53

+0.1 (+1.56%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.6%
Inst Owner Change0%
Ins Owners9.93%
Ins Owner Change0%
Market Cap106.91M
Revenue(TTM)N/A
Net Income(TTM)-6.27M
Analysts82.86
Price Target15.3 (134.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS7.49
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y1%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.49
Altman-Z 7.86
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7423.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1082.25%
EPS Next Y-87.12%
EPS Next 2Y-95.74%
EPS Next 3Y-32.32%
EPS Next 5Y-0.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

MERIDA MERGER CORP I / MCMJ FAQ

Can you provide the ChartMill fundamental rating for MERIDA MERGER CORP I?

ChartMill assigns a fundamental rating of 1 / 10 to MCMJ.


Can you provide the valuation status for MERIDA MERGER CORP I?

ChartMill assigns a valuation rating of 1 / 10 to MERIDA MERGER CORP I (MCMJ). This can be considered as Overvalued.


How profitable is MERIDA MERGER CORP I (MCMJ) stock?

MERIDA MERGER CORP I (MCMJ) has a profitability rating of 1 / 10.